Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
40 studies found for:    melanoma | Open Studies | interleukin-2
Show Display Options
Rank Status Study
21 Recruiting Fosaprepitant for Nausea and Vomiting During High-dose Interleukin-2 (HD IL-2) for Metastatic Melanoma and Renal Cell Carcinoma
Condition: Chemotherapy-induced Nausea and Vomiting
Intervention: Drug: Fosaprepitant
22 Not yet recruiting High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: aldesleukin;   Biological: ipilimumab;   Other: laboratory biomarker analysis
23 Recruiting Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: High Dose Interleukin-2 (IL-2);   Procedure: ACT with TIL Infusion;   Drug: Vemurafenib;   Drug: Lymphodepletion
24 Recruiting Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells;   Drug: non-myeloablative conditioning chemotherapy
25 Recruiting Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Conditions: Melanoma;   Skin Cancer
Interventions: Drug: Interleukin-2;   Drug: Fludarabine;   Drug: Cylcophosphamide;   Genetic: 41BB Selected Tumor Infiltrating Lymphocytes
26 Unknown  The Role of Peptide-Loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2
Condition: Metastatic Melanoma
Intervention: Procedure: Immunotherapy treatment for melanoma
27 Recruiting Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
Condition: Metastatic Melanoma
Interventions: Drug: Ipilimumab;   Procedure: Tumor Infiltrating Lymphocytes (TIL);   Drug: Administration of Lymphodepletion;   Drug: Cyclophosphamide as Part of Lymphodepletion;   Drug: Fludarabine as Part of Lymphodepletion;   Drug: High Dose IL-2;   Biological: Adoptive Cell Therapy with TIL
28 Recruiting Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ziv-Aflibercept;   Biological: Aldesleukin;   Other: Laboratory Biomarker Analysis
29 Recruiting Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Conditions: Recurrent Melanoma of the Skin;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Biological: Therapeutic Tumor Infiltrating Lymphocytes;   Biological: Aldesleukin;   Other: Laboratory Biomarker Analysis
30 Unknown  Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-Depleting Chemotherapy
Condition: Metastatic Melanoma
Intervention: Biological: tumor infiltrating lymphocytes
31 Recruiting Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
Conditions: Desmoplastic Small Round Cell Tumor;   Disseminated Neuroblastoma;   Metastatic Childhood Soft Tissue Sarcoma;   Metastatic Ewing Sarcoma/PNET;   Metastatic Osteosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/PNET;   Recurrent Melanoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma
Interventions: Biological: IL-2;   Biological: GD2Bi-aATC;   Biological: GM-CSF;   Other: laboratory evaluations of immune responses
32 Recruiting Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2
Condition: Metastatic Malignant Melanoma and Renal Cell Carcinoma
Intervention: Biological: Irradiated donor lymphocyte infusion
33 Recruiting "Re-Stimulated" Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Condition: Recurrent, Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Interventions: Biological: Re-stimulated tumor-infiltrating lymphocytes (TILs);   Biological: Interleukin-2
34 Recruiting Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans
Condition: Cancer
Intervention: Biological: Bromelain and Comosain
35 Recruiting A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
Condition: Metastatic Melanoma Stage IV
Interventions: Drug: Arm 1: L19IL2 + Dacarbazine;   Drug: Arm 2: Dacarbazine
36 Recruiting Intratumoral Administration of L19IL2/L19TNF
Condition: Malignant Melanoma, Skin
Intervention: Drug: L19IL2+L19TNF
37 Recruiting Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients
Conditions: Solid Tumour,;   Breast Cancer,;   Metastatic Melanoma,;   Non-small Cell Lung Cancer (NSCLC),
Intervention: Drug: F16IL2 in combination with paclitaxel
38 Recruiting Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
Conditions: Head and Neck Squamous Cell Carcinoma;   Keratinizing Head and Neck Squamous Cell Carcinoma;   Nasopharyngeal Basaloid Squamous Cell Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Stage III Laryngeal Squamous Cell Carcinoma;   Stage III Lip and Oral Cavity Squamous Cell Carcinoma;   Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Squamous Cell Carcinoma;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Tonsillar Squamous Cell Carcinoma
Interventions: Biological: Recombinant Interleukin-15;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
39 Recruiting A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors
Conditions: Melanoma;   Prostate Cancer;   Ovarian Cancer;   Renal Cell Carcinoma;   Colorectal Carcinoma;   Pancreatic Carcinoma;   Non-small Cell Lung Carcinoma;   Solid Tumors
Interventions: Drug: AM0010;   Drug: Paclitaxel or Docetaxel and Carboplatin or Cisplatin;   Drug: FOLFOX4
40 Unknown  Trial of pIL-12 Electroporation Malignant Melanoma
Condition: Melanoma
Interventions: Biological: Plasmid INTERLEUKIN-12;   Device: Intratumoral Electroporation

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page   
Indicates status has not been verified in more than two years